ProCE Banner Activity

当代 HIV 管理:ART 中的新兴范式

Slideset Download
下载本专家编写幻灯片,考虑与一线 ART、长效抗逆转录病毒药物和 ART 2 药方案相关的重要临床问题,特别是新兴策略的作用。

Released: January 20, 2022

Expiration: January 19, 2023

No longer available for credit.

Share

Faculty

Joseph J. Eron

Joseph J. Eron, Jr., MD

Professor of Medicine
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina

Princy N. Kumar

Princy N. Kumar, MD

Professor of Medicine and Microbiology
Division of Infectious Diseases
Georgetown University Hospital
Division Chief
Division of Infectious Diseases and Travel Medicine
Department of Internal Medicine
Medstar Georgetown University Hospital
Washington, DC

David A. Wohl

David A. Wohl, MD

Professor of Medicine
School of Medicine
Site Leader, Global Clinical Trials Unit-Chapel Hill
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

教育补助金提供者

ViiV Healthcare

Faculty Disclosure

Primary Author

Joseph J. Eron, Jr., MD

Professor of Medicine
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina

Joseph J. Eron, Jr.(医学博士)透露,他已收到 Gilead Sciences、Janssen、Merck 和 ViiV Healthcare 的咨询费以及来自 Gilead Sciences、Janssen 和 ViiV Healthcare 的研究支持资金。

Princy N. Kumar, MD

Professor of Medicine and Microbiology
Division of Infectious Diseases
Georgetown University Hospital
Division Chief
Division of Infectious Diseases and Travel Medicine
Department of Internal Medicine
Medstar Georgetown University Hospital
Washington, DC

Princy N. Kumar(医学博士、FIDSA、MACP)透露,她从 Amgen、Gilead Sciences、GlaxoSmithKline、Merck 和 Theratechnologies 公司获得了咨询费,从 Gilead Sciences、GlaxoSmithKline、Merck 和 Theratechnologies 公司获得了研究资助金,并在 Gilead Sciences、GlaxoSmithKline、Johnson & Johnson、Merck 和 Pfizer 拥有所有者权益。

David A. Wohl, MD

Professor of Medicine
School of Medicine
Site Leader, Global Clinical Trials Unit-Chapel Hill
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

David A. Wohl(医学博士)透露,他已收到 Gilead Sciences、Janssen、Merck 和 ViiV Healthcare 的咨询费以及 Gilead Sciences、Merck 和 ViiV Healthcare 的研究资金。